To be honest I see your point, but at the end of the day this is a company that is close to entering a phase 3 end stage trial in Europe with virtually no legitimate competition at sub 200M MC. (I’m not considering Exondys-51 as actual competition). I think that post december we should see some organic upwards growth once all of our traders have churned and instos have consolidated their positions.
$15m cap raise Fresh Equities at 24c, page-322
-
- There are more pages in this discussion • 534 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
